Amed.O
AMED.O operates within the Health Care Providers & Services industry, generating revenue through healthcare-related activities, though specific operational details are unclassified in the available data.
Business. AMED.O operates within the Health Care Providers & Services industry, generating revenue through healthcare-related activities, though specific operational details are unclassified in the available data.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
- Congressional trades
- CongressLisa McClain — Amedisys Inc - Common Stock2025-08-18 · Republican · MI · Sale · $1,001 - $15,000
- CongressLisa McClain — Amedisys Inc - Common Stock2025-06-09 · Republican · MI · Purchase · $1,001 - $15,000
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
AMED.O operates within the Health Care Providers & Services industry, generating revenue through healthcare-related activities, though specific operational details are unclassified in the available data.
AMED.O maintains a conservative capital structure with a debt-to-equity ratio of 0.33 and a current ratio of 1.23, indicating adequate short-term liquidity despite a medium liquidity risk assessment. The balance sheet shows total assets of $2.14 billion against total liabilities of $1.00 billion, resulting in total equity of $1.13 billion. The company holds $303.2 million in cash and equivalents, which partially offsets its $377.3 million in long-term debt, leading to a net cash position that is technically negative when total debt is considered, as flagged in the risk assessment.
Profitability metrics indicate modest returns, with a return on equity (ROE) of 7.55% and a return on assets (ROA) of 4.0%. The company generated $2.35 billion in revenue, resulting in a gross profit of $1.02 billion and an operating income of $94.5 million. Net income stands at $43.2 million, reflecting a net margin of approximately 1.84%. These returns are derived from a business model that generates significant gross margins but faces substantial operating expenses, compressing bottom-line profitability.
Segment and geographic data are not provided in the available input, preventing a detailed analysis of revenue concentration or regional exposure. The classification source indicates the company operates in Health Care Providers & Services, but without specific segment breakdowns, the revenue mix remains opaque. The lack of segment data limits the ability to assess diversification risks or identify primary growth drivers within specific business lines.
Growth trajectory analysis is constrained by the absence of historical period data in the input. The current financial snapshot provides a single-period view of revenue and net income, but without year-over-year or quarterly trend data, it is not possible to evaluate the momentum or consistency of the company's financial performance. The latest actual EPS is reported as $4.32, corresponding to the net income of $43.2 million and basic shares outstanding of 32.9 million.
Risk factors include a medium liquidity risk and low dilution risk. A key flag notes that net cash is negative after subtracting total debt, which may constrain financial flexibility. The company's ESG profile shows a total score of 53.75 with a grade of B-, characterized by a strong social pillar score of 66.29 but a weaker environment pillar score of 28.14. The governance pillar scores 51.50, and the controversies score is 79.63, indicating relatively few controversies.
Recent observations include analyst estimates confirming the last actual revenue of $2.35 billion and EPS of $4.32. No specific filing, news, or transcript events are detailed in the input beyond these standard financial metrics and ESG scores. The company's operational stability appears supported by positive operating cash flow of $221.7 million and free cash flow of $91.3 million, despite the capital expenditure of $7.4 million.
- AMED.O generates $2.35 billion in revenue with a gross profit of $1.02 billion, but net income is compressed to $43.2 million due to operating expenses.
- The company maintains a conservative leverage profile with a debt-to-equity ratio of 0.33 and a current ratio of 1.23.
- Returns are modest, with an ROE of 7.55% and ROA of 4.0%, reflecting the margin compression in the healthcare services sector.
- Liquidity risk is assessed as medium, primarily due to a negative net cash position when total debt is subtracted from cash and equivalents.
- Dilution risk is low, with basic and diluted shares outstanding being identical at 32.9 million.
- ESG performance is mixed, with a B- grade driven by strong social scores but weak environmental metrics.
Bull / Bear case
analysis pipelineIn focus — financials by report
Revenue $621.9M, +5,2% YoY; Operating income −12,7% YoY.
- ▍Revenue $621.9M, +5,2% YoY
- ▍Operating income −12,7% YoY
- ▍Net income −13,1% YoY
- ▍Free cash flow −5,0% YoY
- ▍Net margin 4.5%
Revenue $594.8M, +4,1% YoY; Operating income +37,1% YoY.
- ▍Revenue $594.8M, +4,1% YoY
- ▍Operating income +37,1% YoY
- ▍Net income +323,7% YoY
- ▍Free cash flow +187,2% YoY
- ▍Net margin 10.3%
Revenue $598.1M, +4,8% YoY; Operating income −157,7% YoY.
- ▍Revenue $598.1M, +4,8% YoY
- ▍Operating income −157,7% YoY
- ▍Net income −205,5% YoY
- ▍Free cash flow −136,4% YoY
- ▍Net margin -3.4%
Revenue $587.7M, +5,7% YoY; Operating income −28,1% YoY.
- ▍Revenue $587.7M, +5,7% YoY
- ▍Operating income −28,1% YoY
- ▍Net income −34,9% YoY
- ▍Free cash flow −22,0% YoY
- ▍Net margin 2.9%
Revenue $591.2M; Operating income $52.2M.
- ▍Revenue $591.2M
- ▍Operating income $52.2M
- ▍Net margin 5.5%
Revenue $571.4M; Operating income $31.6M.
- ▍Revenue $571.4M
- ▍Operating income $31.6M
- ▍Net margin 2.5%
Revenue $570.8M; Operating income $34.0M.
- ▍Revenue $570.8M
- ▍Operating income $34.0M
- ▍Net margin 3.4%
Revenue $556.2M; Operating income $42.2M.
- ▍Revenue $556.2M
- ▍Operating income $42.2M
- ▍Net margin 4.7%
Revenue $2.35B, +5,0% YoY; Operating income +87,6% YoY.
- ▍Revenue $2.35B, +5,0% YoY
- ▍Operating income +87,6% YoY
- ▍Net income +543,5% YoY
- ▍Free cash flow +166,4% YoY
- ▍Net margin 1.8%
Revenue $2.24B, +0,6% YoY; Operating income −72,1% YoY.
- ▍Revenue $2.24B, +0,6% YoY
- ▍Operating income −72,1% YoY
- ▍Net income −108,2% YoY
- ▍Free cash flow −81,1% YoY
- ▍Net margin -0.4%
Revenue $2.22B, +0,4% YoY; Operating income −28,2% YoY.
- ▍Revenue $2.22B, +0,4% YoY
- ▍Operating income −28,2% YoY
- ▍Net income −43,3% YoY
- ▍Free cash flow −33,9% YoY
- ▍Net margin 5.3%
Revenue $2.21B, +6,9% YoY; Operating income +14,9% YoY.
- ▍Revenue $2.21B, +6,9% YoY
- ▍Operating income +14,9% YoY
- ▍Net income +13,9% YoY
- ▍Free cash flow +10,9% YoY
- ▍Net margin 9.4%
Valuation TTM
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Reference data
- Cash Conversion Ratiooperating_cash_flow / net_income
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Capex To Revenuecapital_expenditure / revenue
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Return On Equitynet_income / total_equity
- Amedisys Inc Market data — financials · 2026-08-01
- Amedisys Inc Market data — analyst estimates · 2026-08-01
- Amedisys Inc Market data — ESG · 2026-08-01
Ownership & reference
Top holders
- Investment Managers · as of 2024-06-300,01 %$285M
- Investment Managers · as of 2024-12-310,00 %$5M
- Institutional Investor · as of 2022-09-300,00 %$0M